ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)
CAPS Rating:
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
RSS Headlines
Fool UK
Recs
Phase three drug approval coming soon